Movement Alert｜AbCellera Biologics Falls 8.02% in Regular Trading, Life Sciences Sector Broadly Under Pressure Post Dilutive Offering

Market Focus

Aug 29

On August 29, AbCellera Biologics fell 8.02% in regular trading, trading at $11.395/share, with turnover of $33.19 million.

The decline came amid broad-based weakness across the Life Sciences Tools & Services sector. Among sector peers, Tempus AI fell 8.16%, Agilent declined 2.74%, Thermo Fisher Scientific dropped 2.05%, IQVIA fell 0.57%, and Danaher slipped 0.18%.

Adding to selling pressure, AbCellera completed a $200 million public offering on August 13, issuing approximately 17.4 million shares at $9.75 each along with pre-funded warrants for about 3.1 million additional shares. The dilutive offering, intended to fund R&D and clinical advancement of its lead program ABCL635, may continue to weigh on shares as newly issued stock enters the float. The stock had previously surged over 33% on August 10 following positive Phase 2 data for ABCL635 in treating menopausal hot flashes.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1139190275"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1139190275\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1139190275?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-29 00:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1139190275","market":"us","top_or_hot":-1,"title":"Movement Alert｜AbCellera Biologics Falls 8.02% in Regular Trading, Life Sciences Sector Broadly Under Pressure Post Dilutive Offering","media":"Market Focus","content":"<p><p>On August 29, AbCellera Biologics fell 8.02% in regular trading, trading at $11.395/share, with turnover of $33.19 million.</p><p>The decline came amid broad-based weakness across the Life Sciences Tools & Services sector. Among sector peers, Tempus AI fell 8.16%, Agilent declined 2.74%, Thermo Fisher Scientific dropped 2.05%, IQVIA fell 0.57%, and Danaher slipped 0.18%.</p><p>Adding to selling pressure, AbCellera completed a $200 million public offering on August 13, issuing approximately 17.4 million shares at $9.75 each along with pre-funded warrants for about 3.1 million additional shares. The dilutive offering, intended to fund R&D and clinical advancement of its lead program ABCL635, may continue to weigh on shares as newly issued stock enters the float. The stock had previously surged over 33% on August 10 following positive Phase 2 data for ABCL635 in treating menopausal hot flashes.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AbCellera Biologics Falls 8.02% in Regular Trading, Life Sciences Sector Broadly Under Pressure Post Dilutive Offering</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AbCellera Biologics Falls 8.02% in Regular Trading, Life Sciences Sector Broadly Under Pressure Post Dilutive Offering\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-29 00:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 29, AbCellera Biologics fell 8.02% in regular trading, trading at $11.395/share, with turnover of $33.19 million.</p><p>The decline came amid broad-based weakness across the Life Sciences Tools & Services sector. Among sector peers, Tempus AI fell 8.16%, Agilent declined 2.74%, Thermo Fisher Scientific dropped 2.05%, IQVIA fell 0.57%, and Danaher slipped 0.18%.</p><p>Adding to selling pressure, AbCellera completed a $200 million public offering on August 13, issuing approximately 17.4 million shares at $9.75 each along with pre-funded warrants for about 3.1 million additional shares. The dilutive offering, intended to fund R&D and clinical advancement of its lead program ABCL635, may continue to weigh on shares as newly issued stock enters the float. The stock had previously surged over 33% on August 10 following positive Phase 2 data for ABCL635 in treating menopausal hot flashes.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABCL","symbol_name":"AbCellera Biologics","start_time":0,"source_url":"","article_id":"1139190275","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1139190275","pubTimestamp":1787934627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 29, AbCellera Biologics fell 8.02% in regular trading, trading at $11.395/share, with turnover of $33.19 million.The decline came amid broad-based weakness across the Life Sciences Tools &...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABCL":"AbCellera Biologics"},"translate_title":"走势警报|AbCellera Biologics 常规交易中下跌 8.02%，生命科学板块在稀释发行后普遍面临压力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABCL":1},"content_text":"On August 29, AbCellera Biologics fell 8.02% in regular trading, trading at $11.395/share, with turnover of $33.19 million.The decline came amid broad-based weakness across the Life Sciences Tools & Services sector. Among sector peers, Tempus AI fell 8.16%, Agilent declined 2.74%, Thermo Fisher Scientific dropped 2.05%, IQVIA fell 0.57%, and Danaher slipped 0.18%.Adding to selling pressure, AbCellera completed a $200 million public offering on August 13, issuing approximately 17.4 million shares at $9.75 each along with pre-funded warrants for about 3.1 million additional shares. The dilutive offering, intended to fund R&D and clinical advancement of its lead program ABCL635, may continue to weigh on shares as newly issued stock enters the float. The stock had previously surged over 33% on August 10 following positive Phase 2 data for ABCL635 in treating menopausal hot flashes.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}